Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Liabilities and Shareholders Equity (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $1.1 billion as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 27.4% to $1.1 billion in Q3 2025 year-over-year; TTM through Dec 2025 was $3.5 billion, a 40.91% decrease, with the full-year FY2024 number at $1.4 billion, up 19.09% from a year prior.
  • Liabilities and Shareholders Equity was $1.1 billion for Q3 2025 at Denali Therapeutics, down from $1.2 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.6 billion in Q1 2024 to a low of $1.1 billion in Q3 2025.
  • A 5-year average of $1.4 billion and a median of $1.4 billion in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 133.23% in 2021, then decreased 27.4% in 2025.
  • Denali Therapeutics' Liabilities and Shareholders Equity stood at $1.4 billion in 2021, then rose by 3.99% to $1.5 billion in 2022, then dropped by 20.98% to $1.2 billion in 2023, then increased by 19.09% to $1.4 billion in 2024, then fell by 23.18% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Liabilities and Shareholders Equity are $1.1 billion (Q3 2025), $1.2 billion (Q2 2025), and $1.3 billion (Q1 2025).